celecoxib and eicosapentaenoic acid

celecoxib has been researched along with eicosapentaenoic acid in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Cartwright, C; Chan, D; Felix, E; Fischer, SM; Klein, RD; Madden, T; Menter, DG; Newman, RA; Yang, P	1
Castro, MA; Cerchietti, LC; Navigante, AH	1
Manku, M; Song, C; Zhang, XY	1
Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J	1
Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M	1

Trials

2 trial(s) available for celecoxib and eicosapentaenoic acid

Article	Year
Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutrition and cancer, 2007, Volume: 59, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Appetite; C-Reactive Protein; Cachexia; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatigue; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Muscle Strength; Patient Compliance; Pyrazoles; Sulfonamides; Syndrome; Weight Gain	2007
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. BMC cancer, 2011, Nov-23, Volume: 11 Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Eicosapentaenoic Acid; Feasibility Studies; Female; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; New Zealand; Patient Satisfaction; Prospective Studies; Pyrazoles; Resistance Training; Sulfonamides	2011

Article

Year

Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.

Nutrition and cancer, 2007, Volume: 59, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Appetite; C-Reactive Protein; Cachexia; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatigue; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Muscle Strength; Patient Compliance; Pyrazoles; Sulfonamides; Syndrome; Weight Gain

2007

A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

BMC cancer, 2011, Nov-23, Volume: 11

Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Eicosapentaenoic Acid; Feasibility Studies; Female; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; New Zealand; Patient Satisfaction; Prospective Studies; Pyrazoles; Resistance Training; Sulfonamides

2011

Other Studies

4 other study(ies) available for celecoxib and eicosapentaenoic acid

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. Journal of lipid research, 2004, Volume: 45, Issue:6 Topics: Alprostadil; Celecoxib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; DNA; Eicosapentaenoic Acid; Humans; Lung Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides	2004
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Jan-07, Volume: 29, Issue:1 Topics: Analysis of Variance; Animals; Celecoxib; Corticosterone; Corticotropin-Releasing Hormone; Cyclooxygenase Inhibitors; Depressive Disorder; Dinoprostone; Disease Models, Animal; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Exploratory Behavior; Gene Expression Regulation; Hippocampus; Interleukin-1; Male; Maze Learning; Nerve Growth Factor; Olfactory Bulb; Phospholipases A2; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides	2009
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays	2021